Indaptus Therapeutics Stock Today
| INDP Stock | USD 0.31 0.01 3.13% |
PerformanceVery Weak
| Odds Of DistressLow
|
Indaptus Therapeutics is selling at 0.31 as of the 16th of June 2025; that is 3.13 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.31. Indaptus Therapeutics has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 18th of March 2025 and ending today, the 16th of June 2025. Click here to learn more.
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 16.03 M outstanding shares of which 1.02 M shares are currently shorted by private and institutional investors with about 1.56 trading days to cover. More on Indaptus Therapeutics
Moving together with Indaptus Stock
Moving against Indaptus Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Indaptus Stock Highlights
| CEO Director | Jeffrey JD |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Indaptus Therapeutics (INDP) is traded on NASDAQ Exchange in USA. It is located in Three Columbus Circle, New York, NY, United States, 10019 and employs 7 people. Indaptus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.21 M. Indaptus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.03 M outstanding shares of which 1.02 M shares are currently shorted by private and institutional investors with about 1.56 trading days to cover.
Indaptus Therapeutics currently holds about 33.01 M in cash with (12.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Indaptus Therapeutics Probability Of Bankruptcy
Ownership AllocationIndaptus Therapeutics has a total of 16.03 Million outstanding shares. Indaptus Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Indaptus Ownership Details
Indaptus Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Indaptus Therapeutics market risk premium is the additional return an investor will receive from holding Indaptus Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.35) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (1.55) | |||
| Treynor Ratio | 10.08 |
Indaptus Stock Against Markets
Indaptus Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| Jeffrey Meckler | CEO Director | Profile | |
| Walt Esq | Chief Officer | Profile | |
| Michael Newman | Chief Founder | Profile | |
| Boyan MD | Chief Officer | Profile |
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.